Emyria Ltd has released a press release.
Pause in Trading
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Positive animal data for Emyrias ultra-pure CBD capsule
- Positive initial MDMA-analogue screening results
- Emyria receives $1,162,000 R&D Tax Incentive Refund
- Emyria Welcomes Tattarang as Strategic Investor
- MDMA Analogue Development Milestone
Later from Emyria
- Emyria adds wearables to psychedelic-assisted therapy trials
- Notification regarding unquoted securities - EMD
- Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
- Application for quotation of securities - EMD
- Emyria grows its novel MDMA-analogue library
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria